BHB Therapeutics, Ltd. is a joint partnership between Juvenescence and The Buck Institute for Research on Aging.

The company will focus on novel approaches to inducing a state of ketosis, which may have protective effects against age-related disease. Ketosis is the state where the body burns fat instead of carbohydrates, increasing the production of anti-inflammatory ketone bodies.

The work is based on the research in the labs of Drs. Eric Verdin, MD and John Newman, MD, PhD. This work centers on the emerging signaling functions of a metabolite created by the body during fasting or exercise, the ketone body beta-hydroxybutyrate (BHB). They have discovered that BHB helps the body respond to stresses, and that long-term exposure to ketone bodies following a ketogenic diet can extend healthy lifespan in model systems.

BHB Therapeutics is part of our continuing commitment to develop and bring products to consumers that have a strong evidence of providing scientific benefit to an aging population.